Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Irinotecan and Panitumumab as Second-Line Therapy for Patients With Advanced Esophageal Adenocarcinoma

NCT00836277 is registered in ClinicalTrials.gov with Weijing Sun, MD, FACP as lead sponsor.

NCT NCT00836277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00836277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Irinotecan and Panitumumab as Second-Line Therapy for Patients With Advanced Esophageal Adenocarcinoma
Lead sponsor
Weijing Sun, MD, FACP
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2009
Completion date
August 31, 2015
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer